DGX vs IQV
Quest Diagnostics and IQVIA, both Healthcare
IQVIA is the larger company at $28B against $22B. On trailing earnings DGX is the cheaper of the two at a P/E of 24.5 against 32.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year IQV returned +37% against +28% for DGX. The RyuScore puts IQV ahead, 70 against 63 out of 100.
| Figure | DGX | IQV |
|---|---|---|
| Last close | $231 | $260 |
| Market cap | $22B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.5 | 32.3 |
| 1-year return | +28% | +37% |
| 5-year return | +65% | +1.7% |
| RyuScoresector-relative, 1–10 | 63/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $3.0B in Q2 2026, net income $320M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.